{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T02:59:08Z","timestamp":1785466748965,"version":"3.56.0"},"reference-count":48,"publisher":"American Chemical Society (ACS)","issue":"6","license":[{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/na","name":"NHC Key Laboratory of Nuclear Technology Medical Transformatio","doi-asserted-by":"publisher","award":["2023HYX035"],"award-info":[{"award-number":["2023HYX035"]}],"id":[{"id":"10.13039\/na","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/na","name":"Central Guidance for Local Science and Technology Development Projects of Mianyang","doi-asserted-by":"publisher","award":["2025ZYDF020"],"award-info":[{"award-number":["2025ZYDF020"]}],"id":[{"id":"10.13039\/na","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,17]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Triple-negative breast cancer (TNBC) is highly aggressive with limited diagnostic and therapeutic options. ADAM9 is overexpressed in TNBC and may serve as a theranostic target. Therefore, this study aims to develop [177Lu]Lu-DOTA-48HZ810, an ADAM9-targeted probe, and evaluate its targeting specificity, imaging capability, efficacy, and safety in TNBC models. ADAM9 expression in TNBC cells was assessed by flow cytometry, and the probe was constructed by conjugating 177Lu to the ADAM9-specific antibody 48HZ810 via DOTA, after which binding specificity, affinity, and internalization were evaluated using radioligand binding, immunoreactive fraction, and internalization assays. In vivo targeting and pharmacokinetics were further analyzed by SPECT\/CT imaging and biodistribution studies, while efficacy, safety, and mechanisms were assessed via tumor growth, body weight, survival, hematology, histopathology, and immunofluorescence. High ADAM9 expression was confirmed in BT-549 cells, and [177Lu]Lu-DOTA-48HZ810 showed &amp;gt;99% radiochemical purity and stability, high affinity (Kd: 3.75 \u00b1 0.72 nmol\/L), and specificity (Bmax: 422.5 \u00b1 17.85 nmol). The tumor was clearly visualized at 72 h, with peak uptake at 96 h (8.56 \u00b1 0.69%ID\/g), and the probe significantly inhibited tumor growth (TGI: 46.04% vs antibody: 18.14%) and improved survival (70% vs antibody: 50% vs control: 0%), with no significant toxicity observed. The antitumor activity was mediated by DNA damage, apoptosis induction, and proliferation suppression. Overall, the first ADAM9-targeted theranostic probe, [177Lu]Lu-DOTA-48HZ810, was successfully developed, demonstrating excellent tumor targeting, antitumor efficacy, and safety in TNBC models, and validating ADAM9 as a viable theranostic target.<\/jats:p>","DOI":"10.1021\/acs.bioconjchem.6c00126","type":"journal-article","created":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T19:17:54Z","timestamp":1779218274000},"page":"1210-1221","source":"Crossref","is-referenced-by-count":0,"title":["A Theranostic\nStudy of 177Lu-Labeled Anti-ADAM9\nAntibody for the Treatment of Triple-Negative Breast Cancer"],"prefix":"10.1021","volume":"37","author":[{"given":"Huayan","family":"Zhang","sequence":"first","affiliation":[{"name":"Southwest University of Science and Technology , , ,","place":["Mianyang, China, 621000"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingming","family":"Tang","sequence":"additional","affiliation":[{"name":"North Sichuan Medical College , , ,","place":["Nanchong, China, 637000"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofei","family":"Hao","sequence":"additional","affiliation":[{"name":"University of Electronic Science and Technology of China , , ,","place":["Mianyang, China, 621000"]},{"name":"University of Electronic Science and Technology of China , , ,","place":["Mianyang, China, 621000"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binwei","family":"Lin","sequence":"additional","affiliation":[{"name":"University of Electronic Science and Technology of China , , ,","place":["Mianyang, China, 621000"]},{"name":"Mianyang Central Hospital , , ,","place":["Mianyang, China, 621000"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan","family":"Du","sequence":"additional","affiliation":[{"name":"University of Electronic Science and Technology of China , , ,","place":["Mianyang, China, 621000"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hu","family":"Long","sequence":"additional","affiliation":[{"name":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. , ,","place":["Chengdu, China, 611138"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiangjiang","family":"Hu","sequence":"additional","affiliation":[{"name":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. , ,","place":["Chengdu, China, 611138"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Luo","sequence":"additional","affiliation":[{"name":"Central Hosital of Mianyang , , ,","place":["Mianyang, China, 621000"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wu","sequence":"additional","affiliation":[{"name":"Southwest University of Science and Technology , , ,","place":["Mianyang, China, 621000"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6348-0636","authenticated-orcid":true,"given":"Xiaobo","family":"Du","sequence":"additional","affiliation":[{"name":"Southwest University of Science and Technology , , ,","place":["Mianyang, China, 621000"]},{"name":"University of Electronic Science and Technology of China , , ,","place":["Mianyang, China, 621000"]},{"name":"University of Electronic Science and Technology of China , , ,","place":["Mianyang, China, 621000"]},{"name":"Mianyang Central Hospital , , ,","place":["Mianyang, China, 621000"]},{"name":"Mianyang Central Hospital , , ,","place":["Mianyang, China, 621000"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2026,5,19]]},"reference":[{"issue":"1","key":"2026073022121724200_cit1","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s40659-017-0140-9","article-title":"Awareness\nand current knowledge of breast cancer","volume":"50","author":"Akram","year":"2017","journal-title":"Biol.\nRes."},{"issue":"6","key":"2026073022121724200_cit2","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1097\/CCO.0000000000001163","article-title":"Progress in global\nbreast cancer control","volume":"37","author":"Trapani","year":"2025","journal-title":"Curr. Opin. Oncol."},{"issue":"3","key":"2026073022121724200_cit3","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics\n2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for\n36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"Cancer J. Clin."},{"issue":"2","key":"2026073022121724200_cit4","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/s00404-025-08028-0","article-title":"Therapy of early breast\ncancer: current status and perspectives","volume":"312","author":"Tauber","year":"2025","journal-title":"Arch.\nGynecol. Obstet."},{"key":"2026073022121724200_cit5","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.critrevonc.2018.09.004","article-title":"Radiotherapy in triple-negative\nbreast cancer: Current situation and upcoming strategies","volume":"131","author":"He","year":"2018","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"12","key":"2026073022121724200_cit6","doi-asserted-by":"publisher","first-page":"7962","DOI":"10.1097\/JS9.0000000000001799","article-title":"Global biomarker trends in triple-negative\nbreast cancer research: a bibliometric analysis","volume":"110","author":"Wang","year":"2024","journal-title":"Int. J. Surg."},{"issue":"1","key":"2026073022121724200_cit7","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s13045-022-01341-0","article-title":"Recent advances\nin therapeutic strategies\nfor triple-negative breast cancer","volume":"15","author":"Li","year":"2022","journal-title":"J. Hematol.\nOncol."},{"issue":"1","key":"2026073022121724200_cit8","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s13058-020-01296-5","article-title":"Triple-negative\nbreast cancer molecular subtyping and treatment progress","volume":"22","author":"Yin","year":"2020","journal-title":"Breast Cancer Res."},{"issue":"6","key":"2026073022121724200_cit9","doi-asserted-by":"publisher","first-page":"167880","DOI":"10.1016\/j.bbadis.2025.167880","article-title":"Angiogenesis\nand immune microenvironment in triple-negative breast cancer: Targeted\ntherapy","volume":"1871","author":"Zhang","year":"2025","journal-title":"Biochim. Biophys. Acta, Mol. Basis\nDis."},{"issue":"2","key":"2026073022121724200_cit10","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1158\/2159-8290.CD-18-1177","article-title":"Insights into\nMolecular Classifications\nof Triple-Negative Breast Cancer: Improving Patient Selection for\nTreatment","volume":"9","author":"Garrido-Castro","year":"2019","journal-title":"Cancer Discovery"},{"issue":"11","key":"2026073022121724200_cit11","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1038\/s41571-025-01069-z","article-title":"The molecular blueprint\nof targeted radionuclide therapy","volume":"22","author":"Primac","year":"2025","journal-title":"Nat. Rev.\nClin. Oncol."},{"issue":"7","key":"2026073022121724200_cit12","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30379-0","article-title":"Targeted\nradionuclide\ntherapy in combined-modality regimens","volume":"18","author":"Gill","year":"2017","journal-title":"Lancet\nOncol."},{"issue":"11","key":"2026073022121724200_cit13","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.2967\/jnumed.120.248062","article-title":"Combination\nStrategies\nto Improve Targeted Radionuclide Therapy","volume":"61","author":"Chan","year":"2020","journal-title":"J.\nNucl. Med."},{"issue":"1","key":"2026073022121724200_cit14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-024-02041-6","article-title":"Radiopharmaceuticals\nand their applications in medicine","volume":"10","author":"Zhang","year":"2025","journal-title":"Signal Transduction\nTargeted Ther."},{"issue":"Pt B","key":"2026073022121724200_cit15","doi-asserted-by":"publisher","first-page":"124946","DOI":"10.1016\/j.ijpharm.2024.124946","article-title":"Preclinical\nevaluation of 89Zr\/177Lu-labeled amatuximab for theranostic application\nin pancreatic ductal adenocarcinoma","volume":"667","author":"Lu","year":"2024","journal-title":"Int. J.\nPharm."},{"issue":"10","key":"2026073022121724200_cit16","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.3390\/ph15101292","article-title":"[177Lu]Lu-PSMA-617\n(PluvictoTM): The First FDA-Approved Radiotherapeutical\nfor Treatment of Prostate Cancer","volume":"15","author":"Hennrich","year":"2022","journal-title":"Pharmaceuticals"},{"issue":"2","key":"2026073022121724200_cit17","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 Trial of 177Lu-Dotatate\nfor Midgut Neuroendocrine Tumors","volume":"376","author":"Strosberg","year":"2017","journal-title":"N. Engl. J.\nMed."},{"issue":"1","key":"2026073022121724200_cit18","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1080\/19336918.2020.1817251","article-title":"Structure, regulatory factors and cancer-related physiological\neffects of ADAM9","volume":"14","author":"Haoyuan","year":"2020","journal-title":"Cell Adhes. Migr"},{"issue":"20","key":"2026073022121724200_cit19","doi-asserted-by":"publisher","first-page":"7790","DOI":"10.3390\/ijms21207790","article-title":"An Overview\nof ADAM9: Structure, Activation, and Regulation in Human Diseases","volume":"21","author":"Chou","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"7","key":"2026073022121724200_cit20","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1016\/j.biochi.2013.03.001","article-title":"ADAM9 silencing\ninhibits breast tumor cell invasion in vitro","volume":"95","author":"Micocci","year":"2013","journal-title":"Biochimie"},{"key":"2026073022121724200_cit21","doi-asserted-by":"publisher","first-page":"214","DOI":"10.3389\/fmed.2020.00214","article-title":"ADAM9Mediates Triple-Negative Breast Cancer Progression\nvia AKT\/NF-\u03baB Pathway","volume":"7","author":"Zhou","year":"2020","journal-title":"Front. Med."},{"issue":"1","key":"2026073022121724200_cit22","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s00432-004-0619-y","article-title":"Increased expression\nof ADAM family members in human breast cancer and breast cancer cell\nlines","volume":"131","author":"Lendeckel","year":"2005","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"5","key":"2026073022121724200_cit23","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.3892\/ol.2013.1209","article-title":"High expression of a disintegrin and metalloproteinase-9\npredicts a shortened survival time in completely resected stage I\nnon-small cell lung cancer","volume":"5","author":"Zhang","year":"2013","journal-title":"Oncol. Lett."},{"issue":"3","key":"2026073022121724200_cit24","doi-asserted-by":"publisher","first-page":"127","DOI":"10.3109\/08941939.2012.728682","article-title":"Overexpression of ADAM9 Promotes Colon Cancer\nCells Invasion","volume":"26","author":"Li","year":"2013","journal-title":"J. Invest. Surg."},{"issue":"5","key":"2026073022121724200_cit25","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1016\/j.eururo.2007.11.034","article-title":"ADAM9 Expression is\na Significant and Independent Prognostic Marker of PSA Relapse in\nProstate Cancer","volume":"54","author":"Fritzsche","year":"2008","journal-title":"Eur. Urol."},{"issue":"5","key":"2026073022121724200_cit26","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1038\/sj.bjc.6601645","article-title":"ADAM9 expression in\npancreatic cancer is associated with tumour type and is a prognostic\nfactor in ductal adenocarcinoma","volume":"90","author":"Gru\u0308tzmann","year":"2004","journal-title":"Br. J. Cancer"},{"issue":"4","key":"2026073022121724200_cit27","doi-asserted-by":"publisher","DOI":"10.1002\/jcla.23136","article-title":"Aberrant expression\nof ADAM9 in ovarian cancer and its clinical significance","volume":"34","author":"Guo","year":"2020","journal-title":"J. Clin. Lab. Anal."},{"issue":"4","key":"2026073022121724200_cit28","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.31557\/APJCP.2019.20.4.1081","article-title":"ADAM9\nExpression in Uterine Cervical Cancer and Its Associated Factors","volume":"20","author":"Mohd Isa","year":"2019","journal-title":"Asian Pac. J. Cancer Prev."},{"issue":"1","key":"2026073022121724200_cit29","doi-asserted-by":"publisher","first-page":"495","DOI":"10.3892\/ol.2017.7284","article-title":"Overexpression\nof ADAM9 in oral squamous cell carcinoma","volume":"15","author":"Tanasubsinn","year":"2017","journal-title":"Oncol.\nLett."},{"issue":"9","key":"2026073022121724200_cit30","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.3390\/ijms17091276","article-title":"ADAM9 Expression Is\nAssociate with\nGlioma Tumor Grade and Histological Type, and Acts as a Prognostic\nFactor in Lower-Grade Gliomas","volume":"17","author":"Fan","year":"2016","journal-title":"Int. J. Mol.\nSci."},{"issue":"1","key":"2026073022121724200_cit31","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1559-0275-8-9","article-title":"The ADAMs\nfamily of proteases: new\nbiomarkers and therapeutic targets for cancer?","volume":"8","author":"Duffy","year":"2011","journal-title":"Clin. Proteomics"},{"issue":"20","key":"2026073022121724200_cit32","doi-asserted-by":"publisher","first-page":"2282","DOI":"10.2174\/138161209788682415","article-title":"ADAM9 as a\npotential target molecule in cancer","volume":"15","author":"Peduto","year":"2009","journal-title":"Curr. Pharm.\nDes."},{"issue":"12","key":"2026073022121724200_cit33","doi-asserted-by":"publisher","first-page":"BSR20201215","DOI":"10.1042\/BSR20201215","article-title":"microRNA-1298 inhibits\nthe malignant behaviors of breast cancer cells via targeting ADAM9","volume":"40","author":"Chen","year":"2020","journal-title":"Biosci. Rep."},{"key":"2026073022121724200_cit34","doi-asserted-by":"publisher","first-page":"108930","DOI":"10.1016\/j.nucmedbio.2024.108930","article-title":"Target\nengagement of an anti-MT1-MMP antibody for triple-negative breast\ncancer PET imaging and beta therapy","volume":"136-137","author":"Magro","year":"2024","journal-title":"Nucl. Med.\nBiol."},{"issue":"1","key":"2026073022121724200_cit35","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s41181-023-00235-x","article-title":"Preclinical\nevaluation of the theranostic potential of (89)Zr\/(177)Lu-labeled\nanti-TROP-2 antibody in triple-negative breast cancer model","volume":"9","author":"Wu","year":"2024","journal-title":"EJNMMI Radiopharm. Chem."},{"issue":"1","key":"2026073022121724200_cit36","doi-asserted-by":"publisher","first-page":"2529652","DOI":"10.1080\/15384047.2025.2529652","article-title":"USP44 promotes\nchemotherapeutic drug resistance of triple negative breast cancer\nthrough EZH2 protein stability","volume":"26","author":"Wu","year":"2025","journal-title":"Cancer Biol.\nTher."},{"issue":"1","key":"2026073022121724200_cit37","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/s41420-024-01819-5","article-title":"Repurposing\nproteasome inhibitors for improved treatment of triple-negative breast\ncancer","volume":"10","author":"Larsson","year":"2024","journal-title":"Cell Death Discovery"},{"issue":"11","key":"2026073022121724200_cit38","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.3390\/biom10111532","article-title":"Magnoflorine-Isolation\nand the Anticancer\nPotential against NCI-H1299 Lung, MDA-MB-468 Breast, T98G Glioma,\nand TE671 Rhabdomyosarcoma Cancer Cells","volume":"10","author":"Okon","year":"2020","journal-title":"Biomolecules"},{"key":"2026073022121724200_cit39","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/978-1-0716-1362-7_3","article-title":"Thin-Layer\nChromatography","volume-title":"Methods In Molecular Biology","author":"Ho\u0308lzl","year":"2021"},{"issue":"7","key":"2026073022121724200_cit40","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1007\/s44211-022-00127-1","article-title":"Novel separation mode\nof HPLC based on phase-separation multiphase flow","volume":"38","author":"Horikawa","year":"2022","journal-title":"Anal. Sci."},{"issue":"3","key":"2026073022121724200_cit41","doi-asserted-by":"publisher","first-page":"377","DOI":"10.2967\/jnumed.124.268487","article-title":"177Lu-Labeled Anticlaudin\n6 Monoclonal Antibody\nfor Targeted Therapy in Esophageal Cancer","volume":"66","author":"Du","year":"2025","journal-title":"J.\nNucl. Med."},{"issue":"7","key":"2026073022121724200_cit42","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1007\/s13555-023-00947-7","article-title":"Binding,\nNeutralization\nand Internalization of the Interleukin-13 Antibody, Lebrikizumab","volume":"13","author":"Okragly","year":"2023","journal-title":"Dermatol. Ther."},{"issue":"2","key":"2026073022121724200_cit43","doi-asserted-by":"publisher","first-page":"316","DOI":"10.2967\/jnumed.120.259200","article-title":"RADAR Guide:\nStandard Methods for\nCalculating Radiation Doses for Radiopharmaceuticals, Part 1-Collection\nof Data for Radiopharmaceutical Dosimetry","volume":"63","author":"Stabin","year":"2022","journal-title":"J.\nNucl. Med."},{"issue":"11","key":"2026073022121724200_cit44","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0142190","article-title":"Tumor Volume Estimation and Quasi-Continuous\nAdministration\nfor Most Effective Bevacizumab Therapy","volume":"10","author":"Sa\u0301pi","year":"2015","journal-title":"PLoS\nOne"},{"issue":"9","key":"2026073022121724200_cit45","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.2967\/jnumed.124.267667","article-title":"Single Chelator\u2013Minibody\nTheranostic Agents for89Zr PET Imaging and177Lu Radiopharmaceutical\nTherapy of PSMA-Expressing Prostate Cancer","volume":"65","author":"Ho","year":"2024","journal-title":"J. Nucl. Med."},{"issue":"1","key":"2026073022121724200_cit46","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s13238-017-0408-4","article-title":"Pharmacokinetics\nof monoclonal antibodies and Fc-fusion proteins","volume":"9","author":"Liu","year":"2018","journal-title":"Protein Cell"},{"key":"2026073022121724200_cit47","unstructured":"Mather, J. P.; Loo, D. T.\n          ADAM-9\nmodulators; US 8,361,475\nB2, 2013."},{"issue":"12","key":"2026073022121724200_cit48","doi-asserted-by":"publisher","first-page":"3074","DOI":"10.1158\/1535-7163.MCT-13-1001","article-title":"The effect of disintegrin-metalloproteinase\nADAM9 in gastric cancer progression","volume":"13","author":"Kim","year":"2014","journal-title":"Mol. Cancer\nTher."}],"container-title":["Bioconjugate Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acs.bioconjchem.6c00126","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/bcches\/article-pdf\/37\/6\/1210\/66265339\/acs.bioconjchem.6c00126.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/bcches\/article-pdf\/37\/6\/1210\/66265339\/acs.bioconjchem.6c00126.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T02:12:24Z","timestamp":1785463944000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/bcches\/article\/37\/6\/1210\/5233108\/A-Theranostic-Study-of-177Lu-Labeled-Anti-ADAM9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,19]]},"references-count":48,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,5,19]]},"published-print":{"date-parts":[[2026,6,17]]}},"URL":"https:\/\/doi.org\/10.1021\/acs.bioconjchem.6c00126","relation":{},"ISSN":["1043-1802","1520-4812"],"issn-type":[{"value":"1043-1802","type":"print"},{"value":"1520-4812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,19]]}}}